Equities

StemRIM Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
4599:TYO

StemRIM Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)291.00
  • Today's Change-5.00 / -1.69%
  • Shares traded60.60k
  • 1 Year change-16.86%
  • Beta1.1225
Data delayed at least 15 minutes, as of Feb 13 2026 06:30 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

StemRIM Inc. is a Japan-based company mainly engaged in the regenerative medicine business. The Company is engaged in the development and research of medicines based on new action mechanism to promote functional regeneration and healing of biological tissue damaged and lost function due to injury or illness. The Company’s main product is stem cell regeneration-inducing medicine. The stem cell regeneration-inducing medicine is a medicine which can obtain the same therapeutic effect as regenerative medicine only by administering the medicine without using living cells and tissues.

  • Revenue in JPY (TTM)0.00
  • Net income in JPY-1.90bn
  • Incorporated2006
  • Employees45.00
  • Location
    StemRIM Inc3F, Saito Bio-Incubator, 7-7-15, SaitoIBARAKI-SHI 567-0085JapanJPN
  • Phone+81 726487152
  • Websitehttps://stemrim.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CellSeed Inc120.30m-1.03bn11.16bn38.00--7.98--92.80-29.71-29.713.4737.830.05621.224.753,165,816.00-48.11-45.50-51.99-49.2952.7257.47-856.11-478.147.05--0.0949--1.65-6.87-1.57--6.39--
Wakamoto Pharmaceutical Co Ltd9.29bn298.60m11.29bn286.0037.660.9315.241.218.608.60267.77348.390.60061.623.0632,493,160.001.93-0.06782.22-0.078147.7048.653.21-0.12462.42--0.0082--0.6595-6.53-40.86--21.87--
Stella Pharma Corp991.86m-180.01m12.39bn43.00--4.27--12.49-5.29-5.2929.1585.220.19580.10842.6723,066,440.00-3.55-16.41-3.74-18.1987.1587.03-18.15-176.1612.27-26.440.1917--256.62--81.56---21.34--
ReproCell Inc2.52bn-324.61m15.26bn99.00--1.73--6.06-3.42-3.4226.6392.820.23284.155.9225,450,770.00-3.00-4.09-3.63-4.4749.3543.75-12.88-13.664.93--0.00--22.7419.94428.65---6.31--
TAIKO PHARMACEUTICAL CO LTD5.94bn853.00m15.29bn214.0017.781.8413.752.5716.9916.99118.31163.900.4751.432.9527,766,360.006.82--8.43--55.74--14.36--2.68--0.1105--2.81--124.87------
Immuno-Biological Laboratories Co., Ltd.1.03bn363.89m16.10bn58.0044.239.1359.3915.6039.0739.07110.76189.250.54560.86034.8117,786,030.0019.25-4.9622.46-5.7770.3562.7035.27-11.273.962,702.080.0947--18.7110.9533.40------
CanBas Co Ltd (Parent)0.00-1.21bn17.01bn14.00--6.55-----62.53-62.530.00131.710.00----0.00-37.50-57.04-41.74-62.13-------4,587.85----0.00------4.27------
Ohki Healthcare Holdings Co Ltd359.41bn2.43bn18.45bn648.007.350.53826.520.0513178.43178.4326,346.692,435.832.269.834.34554,637,400.001.531.776.237.745.315.260.6770.69770.8306--0.268614.174.424.7419.412.2145.686.47
StemRIM Inc0.00-1.90bn18.55bn45.00--2.70-----30.56-30.560.00109.730.00----0.00-24.08-12.71-24.55-12.88-------167.3547.00--0.00------4.59---22.11--
Astena Holdings Co Ltd62.74bn2.19bn20.18bn1.42k9.060.73134.380.321654.2254.221,555.72671.410.89613.622.88--3.110.95876.261.7634.8530.403.471.050.9228--0.4519114.258.19-0.808186.601.9712.612.38
Fuso Pharmaceutical Industries Ltd62.17bn-4.86bn22.45bn1.34k--0.5851--0.3611-568.90-568.907,280.214,059.080.73073.25--46,394,780.00-5.710.7682-12.181.2926.3926.94-7.821.050.822842.560.4617106.299.315.25-338.78--4.376.45
Renascience Inc86.94m34.67m23.39bn3.00647.1914.30125.43268.982.732.736.84123.380.0478----28,981,330.001.90-8.972.00-9.3595.3184.4439.87-107.53----0.00---31.6613.00143.91------
RaQualia Pharma Inc3.05bn-724.12m27.11bn85.00--4.22--8.89-30.73-30.73132.63247.060.31654.316.1535,872,500.00-7.520.1792-8.400.193174.5586.78-23.750.4534.48-13.690.33540.0063.4512.78-52.95--4.19--
Data as of Feb 13 2026. Currency figures normalised to StemRIM Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.23%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 08 Jan 202682.10k0.13%
BlackRock Fund Advisorsas of 09 Jan 202638.70k0.06%
Schroder Investment Management (Japan) Ltd.as of 25 Apr 202422.60k0.04%
Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 20251.10k0.00%
Daiwa Asset Management Co. Ltd.as of 30 Jun 2025500.000.00%
Meiji Yasuda Asset Management Co. Ltd.as of 29 Nov 20240.000.00%
Mitsubishi UFJ Asset Management Co., Ltd.as of 26 Feb 20240.000.00%
LGT Capital Partners AG (Investment Management)as of 31 May 20250.000.00%
More ▼
Data from 30 Sep 2025 - 03 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.